Financial Performance - The company's operating revenue for 2025 is expected to be CNY 1,057,759,831.41, representing a year-on-year increase of 21.80%[3] - The total profit for the period is projected to be CNY 266,581,965.12, reflecting a growth of 34.83% compared to the previous year[3] - Net profit attributable to shareholders is estimated at CNY 236,929,075.58, up 33.87% year-on-year[3] - The basic earnings per share is expected to be CNY 2.02, which is a 32.89% increase year-on-year[3] Investment and R&D - The company plans to invest CNY 12,027.37 million in R&D, an increase of 2.83% from the previous year[5] - The company continues to advance its "仿创结合" R&D strategy, with 8 drug registration approvals obtained during the year[6] Assets and Equity - Total assets at the end of the reporting period are expected to reach CNY 1,571,093,663.44, a growth of 13.48% from the beginning of the period[3] - Shareholder equity attributable to the company is projected to be CNY 1,306,890,778.00, an increase of 18.17%[3] Sales Growth - The company has achieved significant sales growth in key products, including "复瑞彤" and "波开清" which have contributed to revenue growth[5] Capital Changes - The company has implemented a stock increase plan resulting in a 50.00% increase in share capital to 117,315,990 shares[3]
德源药业(920735) - 2025 Q4 - 年度业绩